SPRC

SciSparc Ltd. [SPRC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SPRC Stock Summary

Top 10 Correlated ETFs

SPRC

Top 10 Correlated Stocks

SPRC

In the News

SPRC Financial details

Company Rating
-
Market Cap
3.9M
Income
-7.71M
Revenue
4.23M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
07 Aug 2023
P/E
-7.89
Forward P/E
-
PEG
-0.35
P/S
8.13
P/B
3.17
P/C
-
P/FCF
-0.86
Quick Ratio
0.9
Current Ratio
1.09
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-48.03
EPS next Y
-
EPS next Q
-
EPS this Y
-14.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
72.99%
Revenue last 5Y
42.04%
Revenue Q/Q
-54.01%
EPS Q/Q
-68.83%
-
-
-
-
SMA20
-18.23%
SMA50
-62.53%
SMA100
-86.74%
Inst Own
-
Inst Trans
-
ROA
-24%
ROE
-36%
ROC
-1.14%
Gross Margin
76%
Oper. Margin
-548%
Profit Margin
-192%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.58-23.66
52W High
-81.04%
52W Low
+336%
RSI
37.61
Rel Volume
0.04
Avg Volume
1.35M
Volume
55.7K
Perf Week
-15.83%
Perf Month
-38.68%
Perf Quarter
-89.84%
Perf Half Y
-73.24%
-
-
-
-
Beta
1.399
-
-
Volatility
0.71%, 0.78%
Prev Close
-7.82%
Price
4.36
Change
11.51%

Something similar

Top by Market Cap
MSFT
VOO
FXAIX
MIX.JO
APC.DE
Top Correlated ETFs
EBIZ
AWAY
DXF.TO
Top Correlated Stocks
INM
INBK
SOFI
IINNW
DOX
Similar Market Cap
NBB.L
DEZU
KZG.L
ODX.L
3LMS.L

Company Profile

Healthcare Biotechnology
  • Volume Average 1.35M
  • Market Capitalization 3.9M
  • Employee 3
  • CEO Mr. Itschak Shrem
  • Headquarters Tel Aviv,IL
  • IPO Date 2021-08-30
  • Website https://scisparc.com

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.